Reach Us +441467840001
Editor - Longqin Hu | The State University of New Jersey | 5452
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Longqin Hu

Longqin Hu
Longqin Hu
The State University of New Jersey


Longqin Hu received his Bachelor degree in Pharmacy in 1984 and a Master’s degree in Medicinal Chemistry in 1987 from the Second Military Medical University in Shanghai, China.  From1988 to 1993, he studied for his Ph.D. degree in Medicinal Chemistry at the University of Kansas under the direction of Professor Michael B. Doughty.  After receiving his Ph.D., he worked as an NIH postdoctoral fellow with Professor Roberta F. Colman in Biochemistry at the University of Delaware.  Dr. Hu started his academic career in 1996 as an Assistant Professor of Medicinal Chemistry at the University of Oklahoma College of Pharmacy.  In 1999, he moved to Rutgers University, rose through the ranks, and is currently a Professor of Medicinal Chemistry in the Department of Medicinal Chemistry, Ernest Mario School of Pharmacy.  He has been a member of the Cancer Institute of New Jersey since 2001.

Research Interest

Synthetic Medicinal Chemistry and Bioorganic Chemistry: enzyme mechanism and inhibition
Design of anticancer prodrugs for the site-specific activation in tumor tissues
Design of inhibitors of protein-protein interactions (Eph receptor antagonists and Keap1-Nrf2 inhibitors)
Development of organic synthetic methodologies



Global Speakers in the subject

Global Experts in the subject